Preventive Health Screening

Definition

Preventive health screening is the use of structured checks, tests, interpretation, and follow-up to identify disease or actionable risk before symptoms become obvious.

Current Synthesis

The wiki treats screening as a workflow rather than a test purchase. 70.医生，你在想什么：少看百度，以及吃药时别吃西柚啊 establishes why it can matter: the body may compensate silently, symptoms can arrive late, and self-observation or internet search cannot replace structured professional assessment.

The Japan sources move screening into system design. vol.120.日本医疗体系的崩溃与重生：医院、药品、医保三角困局的一种解法 treats lifestyle-disease prevention as upstream demand management, while 177.日本医保基金为何要支持免费的国民体检？ shows that free examinations require participation, risk stratification, guidance, insurer accountability, and credible outcomes to become more than report production.

The cancer sources define the technology boundary. Surbhi Sarna, Founder of nVision Medical shows that responsible early detection can require safer access devices, trials, and regulatory validation. VOL.220对话大白牛/Under：莫德纳“定制抗癌疫苗”，离普通人有多远？ reinforces that advanced individualized treatment does not remove the ordinary near-term value of prevention, screening, early diagnosis, and standard care.

The individual and consumer-service cases define how breadth should be used. VOL.139 favors a reasonable baseline plus risk-based additions, contextual interpretation, and continuity for known abnormalities. The Neko Health case in Daniel Ek: Life After Spotify, Broken Healthcare Incentives, Catching Disease Early & AI’s Potential adds a vertically integrated Longitudinal Multimodal Screening model: dense data and annual comparison may improve context, but only if validation, clinician review, and proportionate follow-up prevent more testing from becoming more harm.

Key Claims

• Screening is most useful when symptoms are late or unreliable and an early finding has an actionable path.
• A screening program includes appropriate selection, valid measurement, interpretation, escalation, and follow-up rather than only data collection.
• Baseline tests should be combined with additions based on age, symptoms, exposures, family history, prior findings, and clinical context.
• Repeated multimodal measurements can reveal change, but more tests are not automatically better and AI triage does not replace clinicians.
• Public or insurer-funded programs should be judged by participation, guidance, outcomes, burden, and cost evidence rather than free access alone.
• Diagnostic innovation needs safe access, clinical validation, and regulatory discipline before early-detection ambition becomes responsible care.
• Advanced treatment progress does not eliminate the practical value of prevention and earlier diagnosis.

Evidence

• Patient-literacy baseline: 70.医生，你在想什么：少看百度，以及吃药时别吃西柚啊 explains silent compensation, late symptoms, self-exam limits, and professional assessment.
• System demand management: vol.120.日本医疗体系的崩溃与重生：医院、药品、医保三角困局的一种解法 ties screening to chronic-risk prevention inside an aging insurance system.
• Program accountability: 177.日本医保基金为何要支持免费的国民体检？ connects free checks to insurer responsibility, participation, guidance, mixed outcome evidence, and uncertain savings.
• Diagnostic access and validation: Surbhi Sarna, Founder of nVision Medical grounds ovarian-cancer early detection in device access, clinical studies, FDA clearance, and commercialization capacity.
• Treatment boundary: VOL.220对话大白牛/Under：莫德纳“定制抗癌疫苗”，离普通人有多远？ contrasts individualized melanoma-vaccine excitement with prevention, early detection, and standard care.
• Individual selection and continuity: VOL.139当代打工人体检指南：如何选项目？如何避坑？报告怎么看？公立医院医生来支招 joins baseline checks, targeted additions, contextual report reading, and surveillance of known findings.
• Longitudinal integrated service: Daniel Ek: Life After Spotify, Broken Healthcare Incentives, Catching Disease Early & AI’s Potential describes Neko’s laboratory, imaging, cardiovascular, functional, AI-triage, wearable, and clinician-review workflow.

Counterevidence & Qualifications

Screening can cause false reassurance, false positives, incidental findings, anxiety, radiation exposure, overdiagnosis, overtreatment, inequity, privacy risk, and additional downstream cost. Some diseases still lack accurate and safely accessible early tests. Neko’s scan counts and detection results are founder-reported without sufficient methods or controls to establish outcome benefit. None of the sources supplies a universal test package, interval, or individualized medical recommendation.

What Changed

• Added longitudinal multimodal screening as a promising workflow whose value still depends on validation, clinician review, and follow-up.
• Added the explicit boundary that founder-reported detection rates do not establish population benefit or cost savings.

Related Concepts

• 个体化预防性体检选择 / Individualized Preventive Checkup Selection - risk-based method for choosing baseline and additional tests.
• 体检结果情境化解读 / Screening Result Interpretation - clinical-context layer between a result and a diagnosis.
• 异常发现随访连续性 / Abnormal Finding Follow-up Continuity - surveillance process for known abnormalities.
• Longitudinal Multimodal Screening - repeated multi-signal model added by the Neko case.
• Preventive Care Cost-Savings Uncertainty / 预防医疗控费不确定性 - evidence boundary around fiscal savings.
• Healthcare Payer Horizon Mismatch - incentive barrier when prevention payback exceeds insurer tenure.
• Medical Diagnostic Reasoning - professional reasoning required after a screening signal.
• Ovarian Cancer Diagnostics - cancer-specific access and validation problem.